Associated Papers
A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring HRAS Mutations.
Lee HW et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2020
Select a paper to view details